BioCryst Pharma (NASDAQ:BCRX) Stock, Quote.Headers.trade-ideas

BIOCRYST PHARMACEUTICALS INC

BioCryst Pharma

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

BCRX

Biotech

Earnings

News

Guidance

Health Care

Movers

Trading Ideas

General

BioCryst posted $134.2 million in Q1 revenue, raised 2025 Orladeyo guidance, and now expects full-year profitability and positive cash flow.

BioCryst Pharmaceuticals Soars 23% In One Session - Here&#39;s Why It Surprised Investors

Crude,Oil,Pump,Jack,At,Oilfield,On,Sunset,Backround.,Fossil

Equities

Eurozone

Intraday Update

Markets

GPUS

IART

PTCT

TGTX

Crude Oil Falls Over 2%; ISM Services PMI Rises In April

Display,Of,Stock,Market,Quotes

NSSC

NUTX

PONY

ULCC

Napco Security Technologies Posts Better-Than-Expected Results, Joins Skechers, BioCryst Pharmaceuticals And Other Big Stocks Moving Higher On Monday

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharmaceuticals Inc

Press Releases

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst to Present at Upcoming Investor Conference

BioCryst to Report First Quarter 2025 Financial Results on May 5

BioCryst to Present at Upcoming Investor Conferences

Management

BioCryst Appoints Steve Frank to Board of Directors

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

Beam Therapeutics

CG Oncology

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Denali Therapeutics

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

ImmunityBio

Immunovant

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Kymera Therapeutics

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

Twist Bioscience Corporation - Common Stock

Comments

BioCryst Pharma

BioCryst Pharma (NASDAQ:BCRX) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell